A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow. It includes people whose cancer has come back or hasn't gone away after receiving standard treatments like BCG. It may also include people who, based on their doctor's opinion, cannot receive standard treatments or those treatments

Trial Details

NCT ID

NCT07206225

Phase

PHASE1

Sponsor

Pfizer

Status

RECRUITING

Cancer Type

Bladder Cancer

Interventions

PF-08052667
Sasanlimab
BCG
PF-02921367

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249
Birmingham, Alabama, United States|33.52066,-86.80249
Birmingham, Alabama, United States|33.52066,-86.80249
Birmingham, Alabama, United States|33.52066,-86.80249
Ruskin, Florida, United States|27.72086,-82.43315

Key Eligibility Criteria

18 years of age or older (or the minimum age of consent per local regulations)
Histological diagnosis of high-risk, non-muscle invasive urothelial carcinoma of the bladder defined according to the WHO grading system as carcino…
BCG unresponsive and BCG-exposed cohorts should have persistent or recurrent disease after receiving at least 5 out of 6 doses of the BCG induction…
Have refused or are ineligible or not appropriate for radical cystectomy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →